Leading Companies

Aurealis Therapeutics AG

Aurealis Therapeutics, a Swiss-Finnish private biopharmaceutical company, is entering the clinical trial phase with its patented three-in-one combination product AUP-16 for chronic non-healing wounds and other regenerative diseases. The genetically modified lactic acid bacteria based therapy is designed to improve the quality of life for patients who requires tissue generation for example with diabetic foot ulcer. This is remarkable advancement for people who generally have only had access to medicines that treat symptoms versus promote tissue regeneration itself.

Aurealis Therapeutics AG

Hochbergerstr. 60C
4057 Basel
Switzerland


Industries
Life Science
Bio Technology (Biotech)
Chemical & Pharmaceutical Technology
Country of Origin
Finland
Recommend us
How should we contact you?

Premium Partner

Strategic partners

Institutional partner

Official program